NCT06735001 Identification of the Metabolic Signature of Atrial Fibrillation for Personalized Prevention
| NCT ID | NCT06735001 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Bordeaux |
| Condition | Atrial Fibrillation (AF) |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2025-03-10 |
| Primary Completion | 2029-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2025-03-10 with a primary completion date of 2029-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Atrial fibrillation (AF) is a major public health problem. The efficacy of the existing techniques is limited in the more aggressive forms. It is therefore necessary to develop approaches, in particular the identification of relevant biomarkers, to prevent the onset, recurrence or progression of AF in at-risk patients. The objective of this study is to describe the longitudinal metabolic and biomolecular signature of AF in patients eligible for cardiac ablation.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years, all genders, and ethnic origins * Free, informed, and written consent signed * Person affiliated to or benefiting from a social security scheme Exclusion Criteria: * Age \< 18 years * Lack of informed consent * Gestating women (pregnancy test carried out as part of care for FA patients, contraception, or menopause for women in control groups) * Persons under administrative or judicial protection * Endocarditis or pericarditis in progress or within the 3 last months * Active tumor pathology (benign or malignant) * Chronic inflammation or autoimmune disease * Chronic liver disease * Myocardial infarction within the last 8 weeks
Contact & Investigator
Nicolas DERVAL
PRINCIPAL INVESTIGATOR
University Hospital, Bordeaux
Frequently Asked Questions
Who can join the NCT06735001 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation (AF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06735001 currently recruiting?
Yes, NCT06735001 is actively recruiting participants. Contact the research team at guido.caluori@ihu-liryc.fr for enrollment information.
Where is the NCT06735001 trial being conducted?
This trial is being conducted at Pessac, France.
Who is sponsoring the NCT06735001 clinical trial?
NCT06735001 is sponsored by University Hospital, Bordeaux. The principal investigator is Nicolas DERVAL at University Hospital, Bordeaux. The trial plans to enroll 400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.